BioPharmSignal logoBioPharmSignal

Biotech News

Medicenna to Present at the H.C. Wainwright 28th Annual Global Investment Conference

Medicenna Therapeutics Corp. (MDNA)Medicenna Therapeutics Corp.Conference / presentation

TORONTO and HOUSTON, Sept. 03, 2026 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (TSX: MDNA, OTCQX: MDNAF), a clinical-stage immunotherapy company focused on the development of Superkines targeting cancer, autoimmune, and inflammatory diseases, announced today

Related news

MDNAMedicenna Therapeutics Corp.2026-09-24 11:00 EST

Medicenna Announces Oral Presentation of New Bizaxofusp Results in Recurrent Glioblastoma at the 2026 Society for Neuro-Oncology Annual Meeting

PRLDPrelude Therapeutics2026-09-11 11:01 EST

Prelude Therapeutics to Participate in the H.C. Wainwright 28th Annual Global Investment Conference

MGNXMacroGenics2026-09-09 20:05 EST

MacroGenics to Participate in the H.C. Wainwright 28th Annual Global Investment Conference

ANABAnaptysBio, Inc.2026-09-01 20:15 EST

Anaptys Announces Participation at the H.C. Wainwright 28th Annual Global Investment Conference

ERASErasca2026-09-08 11:00 EST

Erasca to Present at the Morgan Stanley 24th Annual Global Healthcare Conference

REPLReplimune Group2026-09-03 12:00 EST

Replimune to Present at the Cantor Global Healthcare Conference 2026

MDNAMedicenna Therapeutics Corp.2026-10-05 13:00 EST

Medicenna Announces Oral Presentation of Topline Data from the Phase 1/2 ABILITY-1 Study of MDNA11 at SITC 2026

LYELLyell Immunopharma2026-09-14 11:00 EST

Lyell Immunopharma To Participate in the Baird 2026 Global Healthcare Conference

FATEFate Therapeutics2026-09-09 11:00 EST

Fate Therapeutics Announces Encore Clinical Data Presentation of FT819 Off-the-Shelf CAR T-Cell Product Candidate at the CCR – West 2026 Meeting

FATEFate Therapeutics2026-09-03 11:00 EST

Fate Therapeutics to Participate in Fireside Chat at the 2026 Annual Cantor Global Healthcare Conference

View all latest news

Medicenna Therapeutics Corp.

IL-2 Superkine Platform Medicenna Therapeutics develops engineered cytokines and fusion proteins intended to improve antitumor immune activity. Its Superkine platform modifies cytokine receptor selectivity, potency and pharmacology. MDNA11 MDNA11 is a long-acting beta-only IL-2 agonist in the Phase 1/2 ABILITY-1 study. It is being...

Recent company news

MDNAMedicenna Therapeutics Corp.2026-10-05 13:00 EST

Medicenna Announces Oral Presentation of Topline Data from the Phase 1/2 ABILITY-1 Study of MDNA11 at SITC 2026

MDNAMedicenna Therapeutics Corp.2026-10-01 23:00 EST

Medicenna Announces Results of Annual General and Special Meeting of Shareholders

MDNAMedicenna Therapeutics Corp.2026-09-24 11:00 EST

Medicenna Announces Oral Presentation of New Bizaxofusp Results in Recurrent Glioblastoma at the 2026 Society for Neuro-Oncology Annual Meeting

MDNAMedicenna Therapeutics Corp.2026-09-03 11:00 EST

Medicenna to Present at the H.C. Wainwright 28th Annual Global Investment Conference

MDNAMedicenna Therapeutics Corp.2026-08-14 11:00 EST

Medicenna Therapeutics Reports First Quarter Fiscal 2027 Financial Results and Announces Oral Presentations at Upcoming Conferences

Stock data

Close
—
Market cap
—
Exchange
NASDAQ
Sector
Biopharma
Location
United States